Initial Efficacy and Safety Results from ENGOT-ov60/GOG-3052/RAMP 201: A Phase 2 Study of Avutometinib (VS-6766) ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
Journal of Clinical Oncology(2023)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined